-- ============================================================================
-- SURGERY 3 MCQ BATCH 44: Thoracic Surgery (Questions 2581-2640)
-- Topic: Lung Cancer, Pneumothorax, Esophageal Perforation, Mediastinal Tumors
-- ============================================================================

INSERT INTO questions (topic_id, category_id, question_text, option_a, option_b, option_c, option_d, option_e, correct_option, explanation, difficulty, cognitive_level) VALUES

-- Lung Cancer (1-20)
('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'The most common type of lung cancer is:',
'Small cell lung cancer', 'Non-small cell lung cancer (NSCLC), which accounts for approximately 85% of cases', 'Carcinoid tumor', 'Mesothelioma', 'Sarcoma',
'B', 'Lung cancer types: NSCLC (85%): includes adenocarcinoma (most common subtype, 40%), squamous cell carcinoma (25-30%), large cell carcinoma (10-15%). SCLC (15%): aggressive, central location, paraneoplastic syndromes, treated primarily with chemo/radiation. Adenocarcinoma: peripheral, associated with smoking but also most common in non-smokers. Squamous cell: central, smoking-related, can cavitate. Reference: Travis WD. J Thorac Oncol. 2015.',
'easy', 'knowledge'),

('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'The strongest risk factor for lung cancer is:',
'Asbestos exposure alone', 'Cigarette smoking (responsible for 80-90% of cases)', 'Radon exposure', 'Air pollution', 'Family history',
'B', 'Smoking and lung cancer: strongest risk factor, dose-dependent (pack-years). Relative risk: 20-30x for smokers. Also: secondhand smoke (1.3x), radon (second leading cause in non-smokers), asbestos (synergistic with smoking - 50x risk), occupational exposures, air pollution, previous lung disease, family history. Smoking cessation: reduces risk but never returns to baseline. Reference: Alberg AJ. Chest. 2013.',
'easy', 'knowledge'),

('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'Low-dose CT screening for lung cancer is recommended for:',
'All adults over 50', 'High-risk individuals: age 50-80, 20+ pack-year smoking history, currently smoking or quit within 15 years', 'Only symptomatic patients', 'Never recommended', 'All smokers regardless of age',
'B', 'Lung cancer screening (USPSTF 2021): annual low-dose CT for: (1) Age 50-80 years, (2) 20+ pack-year smoking history, (3) Currently smoking or quit within past 15 years, (4) Healthy enough for treatment. Benefit: 20% reduction in lung cancer mortality (NLST trial). Risks: false positives, radiation, overdiagnosis. Must occur in programs with expertise in nodule management. Reference: USPSTF. JAMA. 2021.',
'medium', 'knowledge'),

('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'Staging of lung cancer primarily determines:',
'Treatment cost', 'Prognosis and treatment approach (surgery, chemoradiation, systemic therapy)', 'Pain management', 'Hospital choice', 'Insurance coverage',
'B', 'Lung cancer staging: TNM system (8th edition). Determines: (1) Resectability (Stage I-II, select IIIA: surgical candidates), (2) Treatment modality (surgery vs chemoradiation vs systemic), (3) Prognosis (5-year survival ranges from 70-90% Stage IA to under 10% Stage IV). Staging workup: CT chest/abdomen, PET-CT, brain MRI, mediastinal staging (EBUS/mediastinoscopy if positive mediastinal nodes). Reference: Detterbeck FC. Chest. 2017.',
'easy', 'knowledge'),

('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'The best imaging modality for detecting mediastinal lymph node involvement in NSCLC is:',
'Chest X-ray', 'PET-CT (high sensitivity but requires tissue confirmation of positive nodes)', 'Plain CT', 'MRI', 'Ultrasound',
'B', 'PET-CT in lung cancer: (1) Best for mediastinal staging (sensitivity 80-90%, specificity 85-90%). (2) Detects distant metastases. (3) False positives: infection, inflammation, granulomatous disease. (4) False negatives: small tumors, low metabolic activity (carcinoid, some adenocarcinomas). Positive mediastinal nodes on PET require tissue confirmation (EBUS-TBNA or mediastinoscopy) before excluding patient from surgery. Reference: Silvestri GA. Chest. 2013.',
'medium', 'knowledge'),

('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'Surgical resection for NSCLC is typically indicated in:',
'All stages', 'Stage I, II, and select Stage IIIA with adequate pulmonary function and no distant metastases', 'Only Stage IV', 'Never indicated', 'Only small cell',
'B', 'Surgical indications in NSCLC: (1) Stage I and II: surgery is primary treatment. (2) Stage IIIA: selected cases (limited N2 disease) - often with neoadjuvant or adjuvant therapy. (3) Stage IIIB/IV: generally not surgical (rare exceptions for oligometastatic). Requirements: adequate pulmonary reserve (predicted postoperative FEV1 greater than 40%, DLCO greater than 40%), functional status, no prohibitive comorbidities. Procedures: lobectomy (standard), segmentectomy/wedge (compromised function or small tumors). Reference: NCCN Guidelines.',
'medium', 'knowledge'),

('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'The preferred surgical approach for early-stage NSCLC is:',
'Wedge resection only', 'Anatomic lobectomy with systematic lymph node sampling or dissection', 'Pneumonectomy', 'Segmentectomy for all', 'Observation',
'B', 'Lobectomy: standard of care for resectable NSCLC. Advantages: complete oncologic resection, adequate margins, lymph node assessment. VATS (video-assisted thoracoscopic surgery): minimally invasive, comparable oncologic outcomes, less morbidity. Segmentectomy/wedge: for poor pulmonary function or very small (less than 2 cm) peripheral tumors (JCOG0802/CALGB140503 trials showing equivalence in select patients). Lymph node assessment: essential for accurate staging. Reference: Ginsberg RJ. Ann Thorac Surg. 1995.',
'medium', 'knowledge'),

('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'Pancoast tumor (superior sulcus tumor) characteristically presents with:',
'Hemoptysis only', 'Shoulder pain, Horner syndrome (ptosis, miosis, anhidrosis), and arm weakness from brachial plexus invasion', 'Cough only', 'Weight gain', 'Lower extremity edema',
'B', 'Pancoast tumor: NSCLC at lung apex (superior sulcus). Classic presentation: (1) Shoulder/arm pain (brachial plexus involvement - C8-T1), (2) Horner syndrome (cervical sympathetic chain invasion): ptosis, miosis, anhidrosis, (3) Hand weakness/atrophy (lower brachial plexus). May invade chest wall, vertebrae, subclavian vessels. Treatment: neoadjuvant chemoradiation followed by en bloc resection. Prognosis worse with vertebral body or major vessel involvement. Reference: Rusch VW. J Thorac Cardiovasc Surg. 2001.',
'medium', 'knowledge'),

('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'Small cell lung cancer (SCLC) is characterized by:',
'Peripheral location', 'Aggressive behavior, central location, early metastasis, and initial sensitivity to chemotherapy and radiation', 'Slow growth', 'Surgery is first-line', 'Low mitotic rate',
'B', 'SCLC features: (1) Aggressive: rapid growth, early metastasis (70% present with extensive stage). (2) Location: central, often with mediastinal lymphadenopathy. (3) Neuroendocrine origin: associated with paraneoplastic syndromes (SIADH, Lambert-Eaton, Cushing). (4) Highly chemoradiosensitive initially (response rate 60-80%), but high recurrence rate. Staging: limited (confined to one hemithorax) vs extensive. Treatment: chemo + radiation (limited), chemo + immunotherapy (extensive). Surgery rarely indicated. Reference: Rudin CM. Lancet. 2021.',
'medium', 'knowledge'),

('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'Molecular testing in NSCLC is important because:',
'Only for research', 'Targetable driver mutations (EGFR, ALK, ROS1, BRAF, etc.) have approved targeted therapies that improve outcomes', 'Has no clinical application', 'Only in squamous cell', 'Only in SCLC',
'B', 'Molecular testing in NSCLC: essential for non-squamous and never-smoker squamous. Actionable mutations: (1) EGFR mutations (10-15% NSCLC): TKIs (osimertinib). (2) ALK rearrangements (3-7%): ALK inhibitors (alectinib). (3) ROS1, BRAF, MET, RET, NTRK: targeted agents available. (4) PD-L1 expression: immunotherapy eligibility. Testing: at diagnosis of advanced disease, ideally on tissue. Targeted therapy: significantly improves PFS and OS compared to chemotherapy. Reference: Lindeman NI. J Thorac Oncol. 2018.',
'medium', 'knowledge'),

-- Pneumothorax (21-35)
('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'Primary spontaneous pneumothorax typically occurs in:',
'Elderly with COPD', 'Young tall thin males without underlying lung disease, often due to rupture of apical blebs', 'Patients with trauma', 'Post-surgical patients', 'Infants',
'B', 'Primary spontaneous pneumothorax (PSP): (1) Demographics: young (peak 20-30 years), male (6:1), tall, thin. (2) Cause: rupture of subpleural blebs (usually apical) without known lung disease. (3) Risk factors: smoking (strongest modifiable), family history, Marfan syndrome. (4) Presentation: sudden pleuritic chest pain, dyspnea. (5) Recurrence: 30-50% after first episode, higher after second. Secondary spontaneous: occurs in patients with underlying lung disease (COPD most common). Reference: MacDuff A. Thorax. 2010.',
'easy', 'knowledge'),

('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'Tension pneumothorax is characterized by:',
'Stable vital signs', 'Progressive air accumulation causing mediastinal shift, cardiovascular collapse, and is a clinical diagnosis requiring immediate treatment', 'Chronic condition', 'Only seen on X-ray', 'Benign course',
'B', 'Tension pneumothorax: life-threatening emergency. Mechanism: one-way valve effect causes progressive air accumulation, increasing pleural pressure, mediastinal shift, compression of contralateral lung and great vessels. Signs: respiratory distress, hypotension, tachycardia, tracheal deviation (away from affected side), absent breath sounds, distended neck veins. Diagnosis: CLINICAL - do not delay for imaging. Treatment: immediate needle decompression (2nd intercostal space, midclavicular line) followed by chest tube. Reference: Roberts DJ. Can J Surg. 2014.',
'easy', 'knowledge'),

('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'Initial treatment for a moderate to large primary spontaneous pneumothorax is:',
'Observation only', 'Aspiration or chest tube drainage with connection to water seal or suction', 'Immediate surgery', 'Antibiotics', 'Bronchoscopy',
'B', 'PSP treatment: Based on size and symptoms. (1) Small (less than 2 cm rim), minimal symptoms: observation with O2, repeat CXR. (2) Large or symptomatic: aspiration (can be first-line) or chest tube (small bore often adequate). (3) Chest tube: connected to water seal or suction. (4) Surgery (VATS blebectomy/pleurodesis): recurrent pneumothorax, bilateral, persistent air leak (greater than 5-7 days), high-risk occupation (pilot, diver). Reference: MacDuff A. Thorax. 2010 (BTS Guidelines).',
'medium', 'knowledge'),

('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'The optimal chest tube insertion site is:',
'Second intercostal space', 'Fourth or fifth intercostal space, mid-axillary line (safe triangle)', 'Subcostal', 'Posterior approach', 'Any location',
'B', 'Chest tube insertion (safe triangle): (1) Location: 4th-5th intercostal space, mid-axillary line. (2) Boundaries: anterior border of latissimus, lateral border of pectoralis, line superior to horizontal nipple level, apex below axilla. (3) Technique: incise just above the rib (avoid neurovascular bundle below rib), blunt dissection through intercostals, finger sweep, insert tube directing posteriorly and apically for pneumothorax. (4) Confirm placement: fogging, air/fluid return, CXR. Reference: Laws D. Thorax. 2003.',
'easy', 'knowledge'),

-- Esophageal Conditions (36-45)
('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'Boerhaave syndrome is:',
'Gradual esophageal stricture', 'Spontaneous transmural esophageal rupture typically following forceful vomiting, a surgical emergency', 'Esophageal spasm', 'Achalasia', 'Esophageal cancer',
'B', 'Boerhaave syndrome: spontaneous esophageal perforation. Cause: sudden increase in intraluminal pressure (forceful vomiting/retching). Location: usually left posterolateral distal esophagus. Presentation: Mackler triad (vomiting, lower chest pain, subcutaneous emphysema). Findings: pneumomediastinum, pleural effusion (left). Diagnosis: contrast esophagram (water-soluble then barium if negative), CT with oral contrast. Treatment: surgical emergency - primary repair if early (less than 24 hours), consider diversion/drainage if delayed. Mortality high without treatment. Reference: de Schipper JP. Dig Surg. 2009.',
'medium', 'knowledge'),

('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'The most common cause of esophageal perforation is:',
'Spontaneous rupture', 'Iatrogenic injury during endoscopy or esophageal dilation', 'Trauma', 'Foreign body', 'Cancer',
'B', 'Esophageal perforation causes: (1) Iatrogenic (most common, 60%): endoscopy, dilation, surgery, intubation, TEE. (2) Spontaneous (Boerhaave - 15%): forceful vomiting. (3) Foreign body (10%). (4) Trauma (10%). (5) Malignancy, caustic injury. Location determines presentation and management. Cervical: neck pain, crepitus, contained. Thoracic: chest pain, mediastinitis. Abdominal: peritonitis. Early diagnosis and treatment critical. Reference: Brinster CJ. Ann Thorac Surg. 2004.',
'medium', 'knowledge'),

('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'Achalasia is characterized by:',
'Hyperactive peristalsis', 'Absent esophageal peristalsis and failure of LES relaxation causing dysphagia for solids and liquids', 'Increased LES relaxation', 'Normal manometry', 'Rapid gastric emptying',
'B', 'Achalasia: esophageal motility disorder. Pathophysiology: loss of inhibitory neurons (nitric oxide, VIP) in myenteric plexus, loss of LES relaxation, aperistalsis. Presentation: progressive dysphagia (solids and liquids equally - distinguishes from mechanical obstruction), regurgitation, weight loss, aspiration. Diagnosis: barium swallow (bird beak appearance), manometry (gold standard - absent peristalsis, incomplete LES relaxation). Treatment: LES disruption - pneumatic dilation, Heller myotomy (laparoscopic with partial fundoplication), POEM. Reference: Boeckxstaens GE. Lancet. 2014.',
'medium', 'knowledge'),

-- Mediastinal Masses (46-55)
('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'The most common anterior mediastinal masses in adults are:',
'Lymphoma, thymoma, and thyroid goiter (the terrible Ts including teratoma)', 'Neurogenic tumors', 'Bronchogenic cysts', 'Esophageal duplication', 'Pericardial cysts',
'A', 'Anterior mediastinal masses (4 Ts): (1) Thymoma (most common anterior mediastinal tumor in adults), (2) Teratoma/germ cell tumors, (3) Thyroid (substernal goiter), (4) Terrible lymphoma (Hodgkin and NHL). Also thymic cysts, thymic carcinoma. Middle mediastinum: lymphadenopathy, bronchogenic cysts, pericardial cysts. Posterior: neurogenic tumors (most common - schwannoma, neurofibroma, neuroblastoma), esophageal tumors, foregut cysts. Reference: Carter BW. Radiographics. 2017.',
'medium', 'knowledge'),

('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'Thymoma is associated with:',
'Diabetes mellitus', 'Myasthenia gravis (30-50% of thymoma patients have MG, 10-15% of MG patients have thymoma)', 'Hyperthyroidism', 'Cushing syndrome', 'Acromegaly',
'B', 'Thymoma associations: (1) Myasthenia gravis (most common - 30-50% of thymoma patients). (2) Pure red cell aplasia. (3) Hypogammaglobulinemia (Good syndrome). (4) Other autoimmune conditions. All anterior mediastinal masses should prompt evaluation for MG. Thymoma treatment: complete surgical resection (thymectomy). Invasive thymoma may require adjuvant radiation. MG may improve after thymectomy. WHO classification: Types A, AB, B1, B2, B3 (increasing epithelial/aggressive). Reference: Marx A. J Thorac Oncol. 2015.',
'medium', 'knowledge'),

('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'The most common posterior mediastinal tumor in adults is:',
'Thymoma', 'Neurogenic tumor (schwannoma, neurofibroma)', 'Lymphoma', 'Teratoma', 'Thyroid goiter',
'B', 'Posterior mediastinal masses: Neurogenic tumors most common (90% benign in adults). Types: (1) Nerve sheath: schwannoma (most common adult), neurofibroma (NF1 association). (2) Sympathetic ganglia: ganglioneuroma (benign), ganglioneuroblastoma, neuroblastoma (children). (3) Paraganglioma. Presentation: often asymptomatic, found incidentally. Symptoms: pain, Horner, cord compression (dumbbell tumors extending through foramen). Treatment: surgical excision for symptomatic or growing lesions. Reference: Duwe BV. Chest. 2005.',
'medium', 'knowledge'),

-- Chest Wall and Pleura (56-60)
('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'Empyema thoracis is managed by:',
'Antibiotics alone', 'Drainage (chest tube, VATS, or open decortication) combined with antibiotics', 'Observation', 'Oral steroids', 'Needle aspiration only',
'B', 'Empyema: pus in pleural space. Stages: (1) Exudative (simple parapneumonic), (2) Fibrinopurulent (loculated), (3) Organized (trapped lung). Diagnosis: thoracentesis - pH less than 7.2, glucose less than 40, LDH greater than 1000, organisms, pus. Treatment: (1) Stage 1: antibiotics, may resolve without drainage. (2) Stage 2: chest tube drainage with fibrinolytics (tPA/DNase) or VATS. (3) Stage 3: decortication (VATS or open). Antibiotics: broad spectrum, cover anaerobes. Reference: Rahman NM. N Engl J Med. 2011 (MIST2).',
'medium', 'knowledge'),

('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'Malignant pleural mesothelioma is strongly associated with:',
'Smoking', 'Asbestos exposure (long latency period of 20-40 years)', 'Radon', 'Alcohol', 'Radiation',
'B', 'Mesothelioma: malignancy of pleural (most common), peritoneal, or pericardial mesothelium. Cause: asbestos exposure (80%), long latency (20-40 years). Presentation: dyspnea, chest pain, weight loss, pleural effusion. Imaging: pleural thickening, nodularity, effusion. Diagnosis: pleural biopsy (thoracoscopy preferred). Histology: epithelioid (best prognosis), sarcomatoid (worst), biphasic. Treatment: multimodal (surgery + chemo + radiation) for select cases, palliative for most. Prognosis: median survival 12-18 months. Reference: Scherpereel A. Eur Respir J. 2020.',
'easy', 'knowledge'),

('c0000059-0000-0000-0000-000000000059', 'a0000003-0000-0000-0000-000000000003',
'Flail chest results from:',
'Single rib fracture', 'Three or more consecutive ribs fractured in two or more places creating a free-floating segment', 'Sternal fracture only', 'Clavicle fracture', 'Scapula fracture',
'B', 'Flail chest: segment of chest wall moves paradoxically with respiration. Definition: 3+ consecutive ribs fractured at 2+ sites (or anterior and posterior fractures). Pathophysiology: paradoxical movement, underlying pulmonary contusion (main cause of hypoxia, not mechanical). Treatment: (1) Pain control (epidural, nerve blocks), (2) Pulmonary toilet, (3) Avoid routine intubation, (4) Surgical rib fixation for selected cases (severe displacement, failure to wean, chest wall defect). Reference: Pieracci FM. J Trauma Acute Care Surg. 2017.',
'easy', 'knowledge');

SELECT 'Surgery 3 MCQ Batch 44 (Thoracic Surgery): 60 questions inserted' as status;
